Stock Worth Mentioning Today: Could Rockwell Medical Inc Change Direction After Today’s Big Decline?

Stock Worth Mentioning Today: Could Rockwell Medical Inc Change Direction After Today's Big Decline?

The stock of Rockwell Medical Inc (NASDAQ:RMTI) is a huge mover today! About 270,585 shares traded hands. Rockwell Medical Inc (NASDAQ:RMTI) has risen 8.24% since March 8, 2016 and is uptrending. It has underperformed by 1.08% the S&P500.
The move comes after 7 months negative chart setup for the $336.19 million company. It was reported on Oct, 11 by Barchart.com. We have $5.61 PT which if reached, will make NASDAQ:RMTI worth $40.34 million less.

Analysts await Rockwell Medical Inc (NASDAQ:RMTI) to report earnings on November, 14. They expect $-0.10 EPS, down 100.00% or $0.05 from last year’s $-0.05 per share. After $-0.11 actual EPS reported by Rockwell Medical Inc for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

According to Zacks Investment Research, “Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly.”

Insitutional Activity: The institutional sentiment decreased to 0.9 in Q2 2016. Its down 0.26, from 1.16 in 2016Q1. The ratio fall, as 11 funds sold all Rockwell Medical Inc shares owned while 28 reduced positions. 9 funds bought stakes while 26 increased positions. They now own 10.76 million shares or 10.05% less from 11.96 million shares in 2016Q1.
Barrett Asset Mngmt Ltd Liability owns 10,500 shares or 0.01% of their US portfolio. Tiaa Cref Mgmt Limited Liability Co last reported 0% of its portfolio in the stock. Wealthtrust Axiom Limited Com has 13,300 shares for 0.04% of their US portfolio. Cranbrook Wealth Management Ltd Limited Liability Company holds 0.01% or 2,262 shares in its portfolio. Cutter & Brokerage Inc has 27,725 shares for 0.09% of their US portfolio. Blackrock Grp Inc Ltd accumulated 27,970 shares or 0% of the stock. Manufacturers Life Ins The, a Ontario – Canada-based fund reported 33,780 shares. Royal Commercial Bank Of Canada accumulated 973 shares or 0% of the stock. Teachers Advisors Inc accumulated 0% or 74,948 shares. Retail Bank Of New York Mellon Corporation last reported 244,405 shares in the company. Oppenheimer Com Incorporated last reported 68,301 shares in the company. Schwab Charles Investment Mngmt Inc holds 0% or 78,700 shares in its portfolio. Moreover, Barclays Public Ltd Co has 0% invested in Rockwell Medical Inc (NASDAQ:RMTI) for 17,100 shares. First Republic Investment Inc accumulated 14,306 shares or 0% of the stock. The Connecticut-based Aqr Capital Mgmt Lc has invested 0% in Rockwell Medical Inc (NASDAQ:RMTI).

Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 2 insider sales for $81,968 net activity. $26,991 worth of Rockwell Medical Inc (NASDAQ:RMTI) was sold by HOLT KENNETH L on Friday, August 12.

More notable recent Rockwell Medical Inc (NASDAQ:RMTI) news were published by: Fool.com which released: “3 Ways Rockwell Medical Inc. Could Turn Things Around” on October 07, 2016, also Fool.com with their article: “3 Predictions for Rockwell Medical Inc. in 2016” published on December 10, 2015, Fool.com published: “Will Rockwell Medical Inc. Sink or Swim?” on April 06, 2016. More interesting news about Rockwell Medical Inc (NASDAQ:RMTI) were released by: Fool.com and their article: “Rockwell Medical Stock Upgraded: What You Need to Know” published on August 19, 2016 as well as Benzinga.com‘s news article titled: “Mid-Day Market Update: Rent-A-Center Drops On Disappointing Q3 Outlook; Nymox …” with publication date: October 11, 2016.

RMTI Company Profile

Rockwell Medical, Inc. (Rockwell), incorporated on October 25, 1996, is a biopharmaceutical firm targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with services and products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Firm operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s lead branded drug, Triferic is indicated for iron maintenance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment